# Merck to Present Phase 3 Cancer Trial Results at ESMO 2026

- URL: https://stocks.freetheai.org/news/merck-to-present-phase-3-cancer-trial-results-at-esmo-2026-491cbc
- Published: 2026-10-13T10:45:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [NYSE:MRK](https://stocks.freetheai.org/symbols/NYSE-MRK)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Merck & Co., Inc. (NYSE:MRK) announced that initial results from three pivotal Phase 3 clinical trials will feature during late-breaking Presidential Symposia at the European Society for Medical Oncology Congress 2026 in Madrid from October 23 to October 27. The drugmaker will showcase late-breaking data for intismeran, an investigational mRNA individualized neoantigen therapy developed with Moderna, combined with KEYTRUDA for post-surgery melanoma patients. Merck will also present Phase 3 data for sacituzumab tirumotecan in advanced endometrial cancer and KEYTRUDA monotherapy in first-line endometrial cancer, alongside over 90 additional cancer research abstracts.

The upcoming clinical disclosures highlight Merck's efforts to expand its oncology franchise beyond its established immunotherapies into next-generation treatments. By advancing novel personalized mRNA cancer vaccines and antibody-drug conjugates alongside expanded indications for existing therapies, the company aims to secure long-term growth across broader tumor types as existing treatment paradigms evolve.

Investors and analysts can track updates during Merck's dedicated oncology investor event scheduled for October 26 at 2:30 p.m. Eastern Time in Madrid. Shares of Merck traded slightly lower at $145.40 following the presentation schedule announcement.

## Key points

- Merck will present initial Phase 3 results from three clinical trials at the ESMO Congress 2026 in Madrid from Oct. 23-27.
- Featured studies include mRNA therapy intismeran with KEYTRUDA in melanoma and sacituzumab tirumotecan in endometrial cancer.
- Over 90 additional abstracts covering more than 20 tumor types will be presented throughout the ESMO meeting.
- Merck will host an oncology investor event and webcast on Oct. 26 to provide updates on its strategy.

## Questions and answers

### What oncology data will Merck present at ESMO 2026?

Merck will present first-time Phase 3 results for intismeran with KEYTRUDA in melanoma, sacituzumab tirumotecan in endometrial cancer, and KEYTRUDA monotherapy in first-line endometrial cancer, plus over 90 additional abstracts.

### When is the Merck oncology investor event at ESMO 2026?

Merck will hold an oncology investor event on Monday, Oct. 26, 2026, at 2:30 p.m. Eastern Time (7:30 p.m. CET) via webcast.